Entrada Therapeutics Inc (TRDA)
19.04
-0.92
(-4.61%)
USD |
NASDAQ |
Nov 14, 16:00
19.04
0.00 (0.00%)
Pre-Market: 20:00
Entrada Therapeutics Cash and Short Term Investments (Quarterly): 449.34M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 449.34M |
| June 30, 2024 | 469.75M |
| March 31, 2024 | 327.41M |
| December 31, 2023 | 351.97M |
| September 30, 2023 | 353.58M |
| June 30, 2023 | 376.79M |
| March 31, 2023 | 411.63M |
| December 31, 2022 | 188.71M |
| Date | Value |
|---|---|
| September 30, 2022 | 215.57M |
| June 30, 2022 | 244.25M |
| March 31, 2022 | 263.90M |
| December 31, 2021 | 291.06M |
| September 30, 2021 | 122.17M |
| June 30, 2021 | 136.95M |
| December 31, 2020 | 39.04M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
39.04M
Minimum
Dec 2020
469.75M
Maximum
Jun 2024
282.81M
Average
291.06M
Median
Dec 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 273.78M |
| Catalyst Pharmaceuticals Inc | 442.33M |
| Vertex Pharmaceuticals Inc | 6.524B |
| Assembly Biosciences Inc | 109.22M |
| Sarepta Therapeutics Inc | 1.198B |